Impact of Inappropriate Antibiotic Therapy in Vancomycin-Resistant Enterococcus Bacteremia

BACKGROUND Vancomycin-resistant Enterococcus (VRE) bacteremia has significant morbidity and mortality. Empiric antibiotic regimens for treating patients with risk factors for multidrug-resistant organisms may not have medications directed at treating VRE. STUDY QUESTION To evaluate the impact of antibiotic therapy (and other risk factors) on mortality in VRE bacteremia. STUDY DESIGN We identified 146 patients with VRE bacteremia, admitted at our institution over an 11 years period (2004-2014). All inpatients with an initial positive VRE blood culture were included only once in the analysis. Eighteen patients were excluded from the study because of inability to retrieve medical information regarding one or more important study variables. The retrospectively collected data from electronic medical records of 128 patients were analyzed. RESULTS The inpatient, 30-day, and 1-year mortality rates from VRE bacteremia were 23%, 31%, and 59%, respectively. Only 19% patients were discharged home. Inappropriate antibiotics were prescribed in 19% patients. Appropriate antibiotics were prescribed in 81% patients (62% daptomycin and 37% linezolid); however, only 58% patients received appropriate antibiotics within 24 hours of the reported positive blood cultures. The 30-day and 1-year mortality rates for patients treated with inappropriate antibiotics were 54% and 67% compared with 26% and 50%, respectively, for those treated with appropriate antibiotics. The median survival rate for patients treated with inappropriate antibiotics was 1 month (95% confidence interval: 0.0-1.0) compared with 11 months (95% confidence interval: 4.0-13.0) for those treated with appropriate antibiotics. The advanced patient age (median age 75 years vs. 63 years) was a significant risk factor for inappropriate antibiotic therapy (P value = 0.02). The multivariate Cox regression model revealed inappropriate antibiotic therapy (P value = 0.003), septic shock (P value = 0.0004), albumin (P value = 0.04), and dementia (P value = 0.003) to be associated with 30-day mortality. CONCLUSIONS Our study highlights the detrimental effect of inappropriate antibiotic therapy and other risk factors on morbidity and mortality associated with VRE bacteremia.

[1]  G. Papanicolaou,et al.  Bloodstream infection (BSI) due to Vancomycin-Resistant Enterococcus (VRE) is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: A multicenter, retrospective cohort study. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Mellmann,et al.  Hospital acquired vancomycin resistant enterococci in surgical intensive care patients – a prospective longitudinal study , 2018, Antimicrobial Resistance & Infection Control.

[3]  F. Bange,et al.  Economic burden of nosocomial infections caused by vancomycin-resistant enterococci , 2018, Antimicrobial Resistance & Infection Control.

[4]  A. Bryan,et al.  Optimization of antimicrobial therapy in vancomycin-resistant enterococcal bacteraemia using a rapid detection Gram-positive blood culture assay. , 2017, The Journal of hospital infection.

[5]  Jeng-How Yang,et al.  Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[6]  M. Steed,et al.  Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Chen Chang-hua,et al.  [Mortality analysis of Enterococcus faecium bloodstream infection in central Taiwan]. , 2016, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[8]  M. Rybak,et al.  Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G. Garber,et al.  VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis , 2015, Infection Control & Hospital Epidemiology.

[10]  Jason C. Gallagher,et al.  Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy , 2015, The Annals of pharmacotherapy.

[11]  D. Church,et al.  Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  R. Nation,et al.  Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia , 2014, BMC Infectious Diseases.

[13]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[14]  C. Collins,et al.  Comparative Cost‐effectiveness of Alternative Empiric Antimicrobial Treatment Options for Suspected Enterococcal Bacteremia , 2014, Pharmacotherapy.

[15]  K. Kaye,et al.  Impact of Different Antimicrobial Therapies on Clinical and Fiscal Outcomes of Patients with Bacteremia Due to Vancomycin-Resistant Enterococci , 2014, Antimicrobial Agents and Chemotherapy.

[16]  R. Nation,et al.  Impact of vanB vancomycin-resistant enterococcal bacteraemia analysed as a time-varying covariate on length of hospital stay , 2014, Epidemiology and Infection.

[17]  S. Miyakis,et al.  Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia , 2013, Antimicrobial Agents and Chemotherapy.

[18]  L. Rice,et al.  Trends and Significance of VRE Colonization in the ICU: A Meta-Analysis of Published Studies , 2013, PloS one.

[19]  D. Liew,et al.  Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  A. Cheng,et al.  Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  J. Freedman,et al.  Platelets and the immune continuum , 2011, Nature Reviews Immunology.

[22]  H. Yi,et al.  Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients. , 2009, Journal of Korean Neurosurgical Society.

[23]  S. Han,et al.  Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. , 2009, The Journal of infection.

[24]  G. Bearman,et al.  Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci , 2006, BMC infectious diseases.

[25]  Ronald N. Jones,et al.  A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. , 2000, Diagnostic microbiology and infectious disease.

[26]  M. McCarron,et al.  Septic Shock , 1964, International anesthesiology clinics.